19950 W Country Club Drive
7th Floor

Aventura, FL 33180

International Offices:


+1 (305) 662-8515

  • LinkedIn Social Icon
  • Twitter Social Icon
Asset 211.png

© 2019 by IPD Analytics | Privacy Policy



August 12, 2019

Q&A, Part II: How Payers and Providers are Responding to the
Biosimilar Market

The conversation continues around biosimilar management and strategy in Part II of The Advisory Board Company's blog post. In this feature, IPD’s Executive Clinical Pharmacists, Leslie Fish, Pharm D. and Jeffrey Casberg, RPh discuss how payers are responding to the evolving biosimilar market and what providers need to know to make the most of this evolving space.


Read it now: Q&A, Part II: How payers and providers are responding to the biosimilar market


August 5, 2019

Q&A: What Providers Need to Know About a Changing Biosimilar Market

Two senior members of our Clinical Pharmacy team, Leslie Fish, Pharm D. and Jeffrey Casberg, RPh, recently sat down with the research team at The Advisory Board Company to talk about how the biosimilar market is evolving and why it is critical that health systems develop a cohesive and comprehensive biosimilar strategy.

Read Part I of the conversation featured in their latest blog post now: Q&A: What providers need to know about a changing biosimilar market


August 2, 2019

National Trends in Prescription Drug Expenditures and Projections
for 2019

The cost of prescription drugs continues to be a center of focus for the news media, regulators, payers, providers, manufacturers, and many others across the health care landscape. This important article from AJHP, which leverages IPD’s proprietary data and expert insights on forthcoming approvals from the FDA, addresses some of the critical factors driving these costs.


Read it here: National trends in prescription drug expenditures and projections for 2019


May 9, 2019

The Institute for Clinical and Economic Review (ICER) Will Now Leverage Data and Insights from IPD Analytics

Bay Harbor Islands, FL – May 9, 2019

The Institute for Clinical and Economic Review (ICER) has reached an agreement with  IPD Analytics, LLC (IPD)  whereby ICER will leverage IPD’s data, expertise, and assessments to advance their horizon scanning efforts across the pharmaceutical and biologic markets.

ICER is an independent and non-partisan research organization that objectively evaluates the clinical and economic value of prescription drugs, medical tests, and other health care innovations. IPD combines purpose-built data curation mechanisms with an experienced team of uniquely qualified experts to provide deep, informed, and fully independent analysis on the biopharmaceutical industry’s current state and trajectory.

The collaboration involves ICER incorporating IPD’s proprietary data assets and analyses as a tool to ensure comprehensive and accurate reviews of high-impact, high-cost therapies. By leveraging these capabilities, ICER will benefit from this increased capacity to scan, interpret, and anticipate key shifts in the landscape.

“IPD Analytics is an unbiased, independent organization that works to drive efficiency and transparency in the prescription drug market,” said Steven D. Pearson, MD, MSc, President of ICER. “We value their rigorous and thoughtful analysis of the drug pipeline, and we look forward to using this information as a key resource to support our internal horizon scanning efforts and to inform our process for selecting assessment topics.”

Howard Krass, CEO of IPD Analytics, also shared excitement for the collaboration.  “We believe in ICER’s mission, and are pleased to work with them in furthering our shared goal of enhancing transparency regarding drug availability and pricing.”



About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.


About IPD Analytics

IPD Analytics is a provider of insight, transparency, and efficiency for stakeholders across the pharmaceutical landscape.  The company identifies, projects, and quantifies the impact of competitive landscape shifts in the biopharmaceutical market.  By combining proprietary data with uncommon expertise, IPD syndicates meaningful insights and curated information across four key capabilities: Life Cycle Insights, Payer and Provider Insights, Market and Financial Insights, and Coding and Reimbursement.

Follow IPD Analytics on LinkedIn to learn more.

Media Contact:

Veronica Fowler

+1 (305) 662 - 8515


September 30, 2019

Leslie Fish, RPh, PharmD Participates in the Advisory Board Company's Value Summit

Happy to have one of IPD’s Executive Clinical Pharmacists, Leslie Fish, R.Ph, Pharm.D., participate in The Advisory Board Company's Value Summit to share perspectives on how different parts of the industry define, measure, and drive medical value.


December 19, 2020

Leslie Fish, RPh, PharmD Speaks to Students at UMass

Even with her busy year-end work schedule, our VP of Clinical Pharmacy, Leslie Fish, PharmD, found time to speak on drug pricing to students in the "Health Policy and the Practice of Medicine" interstitial curriculum at University of Massachusetts Medical School.


January 10, 2020

Jeff Casberg, RPh, MS Weighs in on Rybelsus

A recent article in the Pink Sheets quoted Jeff on the comments he provided as a panelist at the ICER meeting on Rybelsus.

Read the article now.


January 23, 2020

Express Scripts Coverage, FDA Label Update Boost Rybelsus

RADAR on Drug Benefits  |  by Sharon Bender  |

Access to Novo Nordisk’s Rybelsus (semaglutide)—the first oral glucagon-like peptide-1 receptor agonist (GLP-1) to treat adults with type 2 diabetes—got a major boost January 17th, 2020 when Novo said Express Scripts, part of Cigna Corp., will cover the agent. Rybelsus was approved in September 2019 and is available as a once-daily tablet version of the drugmaker’s Ozempic (semaglutide), a weekly injection launched in 2018.

“We’ve been keeping a keen eye on the new 2020 formulary postings, watching weekly, and monitoring all the big payers’ formularies, and it’s been interesting to note that it looks as though Novo is still in negotiations” for Rybelsus, Jeffrey Casberg, M.S., R.Ph., Director of Clinical Pharmacy at IPD Analytics, told AIS Health. “You would think by now, more often than not you’d see more formularies updated, and we haven’t seen that yet.” IPD provides drug intelligence and consulting to stakeholders across the pharmaceutical landscape.

Casberg represented the payer community on the Institute for Clinical and Economic Review’s (ICER) November policy roundtable panel in which clinical, manufacturer, payer, and patient advocate participants discussed key questions identified by ICER researchers related to oral semaglutide’s cost-effectiveness. A report of the panel’s recommendations, “Oral Semaglutide for Type 2 Diabetes: Final Policy Recommendations,” was published December 9, 2019 along with ICER’s “Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value, Final Evidence Report.” ICER is an independent non-profit research organization.  see more